Seroprevalence of parvovirus B19 in fibromyalgia syndrome.

Discussion in 'Fibromyalgia Main Forum' started by tansy, Dec 8, 2008.

  1. tansy

    tansy New Member

    Clin Rheumatol. 2008 Dec 5. [Epub ahead of print]

    Buyukkose M, Kozanoglu E, Basaran S, Bayramoglu O, Yarkin F.

    Fizyotip Physical Medicine and Rehabilitation Center, Mersin, Turkey.

    PMID: 19057847

    This study was aimed to evaluate the seroprevalence of parvovirus B19
    in patients with fibromyalgia syndrome (FS).

    Seventy-five patients with FS (44.3 +/- 8.3) and 75 healthy controls
    (44.2 +/- 8.1) were evaluated. Serum anti-B19 IgM and IgG antibodies
    were measured by ELISA technique. Patients were questioned about
    duration of symptoms, characteristic features of FS, and symptoms
    related with viral infection preceding the onset of FS.

    No significant difference was found regarding the prevalence of
    anti-B19 IgM antibodies between the groups (p = 0.494).
    Seropositivity of anti-B19 IgG of the patients was significantly
    higher than control group (81.3% vs. 64% respectively, p = 0.027). No
    statistically significant differences were found regarding to the
    clinical features between fibromyalgia patients with IgG antibody
    compared to those without IgG antibody.

    Parvovirus B19 IgG seropositivity was found to be significantly
    higher in patients with FS. Parvovirus B19 infection might have a
    role in the etiopathogenesis of FS or might act as a triggering factor.